Cellectis SA of France has arranged financing for an ambitious project to produce induced pluripotent stem cells (iPS) on an industrial scale so that they can be used for a range of commercial applications, including the production of red blood cells.
Patients who received tissue-engineered implants to correct for defects in their urethras reported normal functioning of their urethras for up to six years after surgery, according to an observational study in The Lancet.
Evotec AG has announced the establishment of a research collaboration with Harvard University and the Howard Hughes Medical Institute in the US to discover and develop new treatments for diabetes. Financial terms were not disclosed.
Généthon, a not-for profit French biotherapy laboratory, has announced a collaboration with the Wake Forest University School of Medicine in the US to work on the preclinical development of a gene therapy for myotubular myopathy.
Scientists from the Northwestern University Feinberg School of Medicine in the US have reported transforming human embryonic stem cells into a type of neuron that plays a critical role in memory. The findings have been published in Stem Cells.
Researchers at Children’s Hospital in Boston, Massachusetts have reported finding a regulator of gene activity that can instruct epidermal stem cells to grow or stop growing, a finding that may have use for cancer as well as regenerative medicine.
The Renovo Group Plc is reducing its staff and the size of its board of directors in the wake of the failure of a Phase 3 trial of its wound-healing product, Juvista. Recruitment is also being stopped for a trial of a second tissue product.
TiGenix NV of Belgium and Cellerix SA of Spain have agreed to merge creating what is expected to be the largest cell therapy and regenerative medicine company in Europe. It is the most significant corporate transaction in the field of regenerative medicine since the December 2010 alliance between Cephalon Inc and Mesoblast Ltd of Australia
Fate Therapeutics Inc, the San Diego, California-based stem cell company, has announced the departure of its president and chief executive officer, Paul Grayson. Mr Grayson is leaving to form a new company, according to Fate.
Three Dutch organisations are allocating more than €3 million to a project that will develop a method for culturing stem cells for transplants in leukaemia patients. The study will also develop imaging technology to monitor these treatments.